https://doi.org/10.7490/f1000research.1111947.1
Poster
NOT PEER REVIEWED
Download
metrics
VIEWS
218
 
downloads
12
CITE
How to cite this poster:
Savitz A, Xu H, Gopal S et al. Paliperidone Palmitate 3-month versus 1-month formulation in patients with Schizophrenia: a randomized, double-blind, noninferiority study [version 1; not peer reviewed]. F1000Research 2016, 5:961 (poster) (https://doi.org/10.7490/f1000research.1111947.1)
NOTE: it is important to ensure the information in square brackets after the title is included in this citation.

Paliperidone Palmitate 3-month versus 1-month formulation in patients with Schizophrenia: a randomized, double-blind, noninferiority study

Adam Savitz1, Haiyan Xu, Srihari Gopal, Isaac Nuamah, Paulien Ravenstijn, Adam Janik, Alain Schotte, David Hough, Wolfgang Fleischhacker
Author Affiliations
  • Metrics
  • 218 Views
  • 12 Downloads
Browse by related subjects
Published 23 May 2016

Paliperidone Palmitate 3-month versus 1-month formulation in patients with Schizophrenia: a randomized, double-blind, noninferiority study

[version 1; not peer reviewed]

Adam Savitz1, Haiyan Xu, Srihari Gopal, Isaac Nuamah, Paulien Ravenstijn, Adam Janik, Alain Schotte, David Hough, Wolfgang Fleischhacker
Author Affiliations
1 Janssen Research & Development, USA
Presented at
71st Society of Biological Psychiatry Annual Meeting 2016
169th American Psyciatry Association Annual Meeting 2016
54th Annual Meeting of the American College of Neuropsychopharmacology (ACNP) 2015
Abstract
Competing Interests

Dr. Fleischhacker is an employee of the Medical University Innsbruck; and received research grants from Otsuka, Janssen Cilag and Lundbeck; advisory board honoraria from Lundbeck, Roche, Otsuka, Janssen Cilag, Takeda, Amgen, Teva, Boehringer Ingelheim and Targacept; speaker honoraria from Lundbeck, Janssen Cilag, Otsuka, Roche and Takeda; and own stocks of MedAvante. Drs. Savitz, Xu, Gopal, Ravenstijn, Nuamah, Janik, Schotte and Hough, are employees of Janssen Research & Development, LLC, (a Johnson & Johnson company) and hold stock in Johnson & Johnson.

Keywords
long-acting injectable, paliperidone palmitate 1-month, paliperidone palmitate 3-month, relapse-free, schizophrenia
Comments
0 Comments
 
Sign In
If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.

The email address should be the one you originally registered with F1000.

Email address not valid, please try again

You registered with F1000 via Google, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Google account password, please click here.

You registered with F1000 via Facebook, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Facebook account password, please click here.

Code not correct, please try again
Email us for further assistance.
Server error, please try again.